Clinical trial · Observational
Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma
NCT06773377CI-TRIAL-00084654not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. Study the expression of CD44 in various histopathological types of RCC. 2. Study the association between CD44 expression and other clinicopathological parameters 3. study the impact of CD44 expressions in tumor and patients' survival
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Study of the prognostic impact of CD44 on renal cell carcinoma.
- timeFrame
- Baseline
- description
- assess the expression of CD44 in various histopathological types of RCC. understanding their biology is mandatory to define novel potential prognostic and therapeutic targets for all RCC subtypes.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * patient must be more than 18 years * Patients with complete pathological data Exclusion Criteria: * The presence of any other organ malignancies * Patients who lost follow-up after nephrectomy less than 3-year, * Patients with incomplete pathological data
References
Publications (0)
Data not yet available
No reference posted for this study.